封面
市場調查報告書
商品編碼
1667877

短腸症候群市場 - 全球產業規模、佔有率、趨勢、機會和預測,按藥物類別、配銷通路、地區和競爭細分,2020-2030 年

Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球短腸症候群 (SBS) 市值為 8.5402 億美元,預計到 2030 年將達到 12.6538 億美元,預測期內的年複合成長率(CAGR) 為 6.73%。 SBS 是一種罕見且使人衰弱的疾病,會影響消化系統,尤其是小腸。患有 SBS 的人吸收營養和液體的能力會下降,這會導致營養不良、脫水和其他各種健康併發症。近年來,全球SBS市場取得了重大進展,為患者和醫療保健提供者帶來了新的希望。

市場概況
預測期 2026-2030
2024 年市場規模 8.5402 億美元
2030 年市場規模 12.6538億美元
2025-2030 年複合年成長率 6.73%
成長最快的領域 麩醯胺酸
最大的市場 北美洲

SBS 通常因手術切除或損傷大部分小腸而引起,常由先天缺陷、創傷或克隆氏症等疾病等因素引起。根據最近的一項名為「克隆氏症表現型及其與合併症、手術風險、藥物和非藥物治療的關係:IMAGINE 研究中 MAGIC」的研究,日本的一項針對 673 名新診斷的克隆氏症(CD)成年人的研究發現,63%的患者表現出炎症表現型,60%患有回結腸病,49%患有周膿病,49%的周管病變,並且肛管疾病,亞洲各地的研究報告顯示,發炎性疾病的發生率甚至更高,從 66% 到 81% 不等。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第 1 章:產品概述

第 2 章:研究方法

第 3 章:執行摘要

第 4 章:顧客之聲

第5章:全球短腸症候群市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類別(GLP-2、麩醯胺酸和生長激素)
    • 按配銷通路(醫院藥房、網路銷售和零售藥房)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖

第 6 章:北美短腸症候群市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 加拿大
    • 墨西哥

第 7 章:歐洲短腸症候群市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章:亞太地區短腸症候群市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章:南美洲短腸症候群市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章:中東和非洲短腸症候群市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 合併與收購(如有)
  • 產品發布(如果有)
  • 最新動態

第 13 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章:競爭格局

  • Wellspect Healthcare (Dentsply Sirona Company)
  • Emmaus Life Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OPKO Health, Inc.
  • OxThera AB
  • Pfizer Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

第 15 章:策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 19143

The global Short Bowel Syndrome (SBS) market was valued at USD 854.02 million in 2024 and is projected to reach USD 1,265.38 million by 2030, reflecting a compound annual growth rate (CAGR) of 6.73% over the forecast period. SBS is a rare and debilitating condition that impacts the digestive system, particularly the small intestine. Individuals with SBS experience a reduced ability to absorb nutrients and fluids, which can result in malnutrition, dehydration, and various other health complications. In recent years, the global SBS market has experienced significant advancements, bringing new hope to patients and healthcare providers alike.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 854.02 Million
Market Size 2030USD 1265.38 Million
CAGR 2025-20306.73%
Fastest Growing SegmentGlutamine
Largest MarketNorth America

SBS typically arises from the surgical removal or damage of a substantial portion of the small intestine, often caused by factors such as congenital defects, trauma, or diseases like Crohn's disease. According to a recent study titled "Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications, and Nonmedication Approaches: The MAGIC in IMAGINE Study", a study in Japan on 673 newly diagnosed adults with Crohn's disease (CD) found that 63% exhibited an inflammatory phenotype, 60% had ileocolonic disease, and 49% had perianal lesions, with the prevalence of perianal disease (such as abscesses or fistulas) being notably high. Studies across Asia have reported even higher rates of inflammatory disease, ranging from 66% to 81%.

Key Market Drivers

The increasing incidence of Short Bowel Syndrome is driving market growth. As the number of SBS cases rises, the demand for treatments and therapies has surged, contributing to the market's expansion. Pharmaceutical companies are heavily investing in research and development to create medications that enhance nutrient absorption for SBS patients and help them manage their condition. These innovations are a significant factor in the market's growth. Parenteral nutrition, which delivers essential nutrients intravenously, has become a critical treatment for SBS patients, leading to a rise in demand for these solutions and associated equipment. Additionally, enteral nutrition, involving specialized formulas designed for SBS patients, plays a crucial role in managing the condition. Advances in minimally invasive surgical techniques and small bowel transplantation have also improved patient outcomes, further driving market expansion. Increased awareness of SBS and the advocacy efforts of patient groups have led to additional research funding and resources, fostering further market growth. Although SBS is rare, with an estimated prevalence of 1-2 cases per 100,000 individuals annually, its growing recognition is accelerating the development of treatment options.

Key Market Challenges

A major challenge for the SBS market is the limited patient pool. As SBS is classified as a rare disease, the number of diagnosed cases globally is relatively small, limiting the overall market size and the number of patients requiring specialized treatments. This restricted patient base can deter pharmaceutical companies from investing heavily in the development of new therapies, as the potential return on investment is lower. Consequently, promising treatments may not receive the attention they deserve, hindering progress in the field. Additionally, the fragmented nature of the patient pool complicates large-scale clinical trials and the collection of sufficient data to prove the efficacy of new therapies, creating a cycle of underinvestment and delayed progress.

Key Market Trends

Technological advancements have significantly influenced the growth of the global SBS market. Recent medical innovations are improving the management and treatment of SBS, offering hope for affected individuals. Pharmaceutical companies are actively developing new drugs and therapies to address the causes and symptoms of SBS. A notable advancement is Zealand Pharma A/S's phase 3 study of Glepaglutide, a long-acting GLP-2 analog that could potentially outperform existing treatments, such as Teduglutide, due to its benefits, including weekly administration and extended action. Furthermore, the development of specialized nutritional supplements tailored for SBS patients has greatly improved their quality of life.

Key Market Players

  • Wellspect Healthcare (Dentsply Sirona Company)
  • Emmaus Life Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OPKO Health, Inc.
  • OxThera AB
  • Pfizer Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Report Scope

This report provides a detailed analysis of the global Short Bowel Syndrome market, segmented into the following categories, in addition to examining industry trends:

By Drug Class:

  • GLP-2
  • Glutamine
  • Growth Hormone

By Distribution Channel:

  • Hospital Pharmacies
  • Online Sales
  • Retail Pharmacies

By Region:

  • North America:
  • United States
  • Canada
  • Mexico
  • Europe:
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America:
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa:
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

This report includes detailed profiles of the leading companies operating in the SBS market.

Available Customizations: TechSci Research offers tailored customizations of the Global Short Bowel Syndrome market report to meet specific business requirements. The following customization options are available:

  • Company Information: In-depth analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Short Bowel Syndrome Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (GLP-2, Glutamine, and Growth Hormone)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Short Bowel Syndrome Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Short Bowel Syndrome Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Short Bowel Syndrome Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Short Bowel Syndrome Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel

7. Europe Short Bowel Syndrome Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Short Bowel Syndrome Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. United Kingdom Short Bowel Syndrome Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Italy Short Bowel Syndrome Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. France Short Bowel Syndrome Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Short Bowel Syndrome Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Short Bowel Syndrome Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Short Bowel Syndrome Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Short Bowel Syndrome Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Short Bowel Syndrome Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Short Bowel Syndrome Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Short Bowel Syndrome Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel

9. South America Short Bowel Syndrome Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Short Bowel Syndrome Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Short Bowel Syndrome Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Short Bowel Syndrome Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Short Bowel Syndrome Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Short Bowel Syndrome Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Short Bowel Syndrome Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Short Bowel Syndrome Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Wellspect Healthcare (Dentsply Sirona Company)
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Emmaus Life Sciences, Inc.
  • 14.3. Merck & Co., Inc.
  • 14.4. Novartis AG
  • 14.5. OPKO Health, Inc.
  • 14.6. OxThera AB
  • 14.7. Pfizer Inc.
  • 14.8. Swedish Orphan Biovitrum AB
  • 14.9. Takeda Pharmaceutical Company Limited
  • 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer